Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

  • Choose the service you want to log in to:

  • gov.je

    Update your notification preferences

  • one.gov.je

    Access government services

  • CAESAR

    Clear goods through customs or claim relief

  • Talentlink

    View or update your States of Jersey job application

Prescribed List: Changes from 1 August 2017

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made 30 June 2017:

Decision Reference: MD-S-2017-0040

Decision Summary Title :

Prescribed List Changes 1 August 2017

Date of Decision Summary:

26 June 2017

Decision Summary Author:

Prescribing Advisor

Decision Summary:

Public or Exempt?

Public

Type of Report:

Oral or Written?

Written

Person Giving

Oral Report:

N/A

Written Report

Title :

Changes to be made to the Prescribed List as at 1 August 2017

Date of Written Report:

26 June 2017

Written Report Author:

Prescribing Advisor

Written Report :

Public or Exempt?

Public

Subject:  Changes to be made to the Prescribed List (Jersey) as at 1 August 2017

Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 August 2017 as set out in the accompanying report.

 

Reason(s) for Decision:

The Pharmaceutical Benefit Advisory Committee met on 23 May 2017 and has provided the Minister with the accompanying written report setting out its recommendations in respect of amendments to the Prescribed List.   On considering these recommendations, the Minister would like to make the following amendments.

 

New products to be added to the Prescribed List

 

  • Empagliflozin tablets 10mg, 25mg; with metformin 5mg/1000mg, 12.5mg/1000mg, 5mg/850mg, 12.5mg/850mg for the treatment of type 2 diabetes
  • Tiotropium/olodaterol for the treatment of chronic obstructive pulmonary disease (COPD)
  • Budesonide/formoterol 160mcg/4.5mcg, 320mcg/9mcg (DuoResp Spiromax) for the treatment of asthma
  • Cetraben ointment for use as a skin emollient
  • Levonorgestrel intrauterine device 13.5mg (brand name Jaydess) for contraception

 

 

Additional preparations of products already listed

 

 

 

Items to be removed from the Prescribed List

 

  • Dexamethasone preservative-free eye drops 0.1% 0.5mL unit dose

 

Other amendments to the Prescribed List

 

 

The changes reflect current evidence and expert advice, and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs at a proportionate cost to the Fund

Resource Implications:

The overall impact of the changes is expected to reduce total expenditure for Pharmaceutical Benefit by approximately £70,000.

Action required:

Business Manager to issue public notice listing amendments and notify all approved medical practitioners and approved contractors.

 

Signature:

Position:

Minister

Date Signed:

 

Date of Decision (If different from Date Signed):

 

Back to top
rating button